Clinical

Misuse of soft mist inhalers (SMIs) is common among patients with chronic obstructive pulmonary disease (COPD), particularly those with low education levels, higher symptom scores, and a shorter disease duration.

There currently are no guidelines on how to treat this patient group, despite a high risk of mortality.

Patients receiving chlorthalidone had lower rates of major cardiovascular (CV) events and noncancer-related deaths vs those receiving hydrochlorothiazide.

The FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation after reviewing the phase 1 safety and efficacy data.

The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.

The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.

A comprehensive discussion on the value of therapies for Alzheimer disease based on cost vs outcome, and unmet needs in the overall treatment landscape.

Experts provide their perspectives on clinical factors taken into consideration when deciding on a treatment plan for a patient with Alzheimer disease.

Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid carcinoma.

Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.

Dr Haumschild drives a discussion surrounding impactful PNH treatment strategies.

Key opinion leaders navigate barriers to optimal care for patients receiving treatment for PNH.

Excessive dietary sodium intake is linked to increased prevalence and severity of atopic dermatitis (AD).

The low-calorie sweetener was associated with incident major adverse cardiovascular event risk, according to one study.

Eli Lilly’s Alzheimer disease drug donanemab unanimously earned the backing of FDA advisers; recent research found 323 active drug shortages in the first 3 months of 2024, marking the highest number since 2001; Microsoft and Google will offer free or discounted cybersecurity services to US rural hospitals to make them less vulnerable to cyberattacks.

Building on prior research, a team tackled mouse-model colon cancer with a novel nonviral nanovector to carry dual–messenger RNA (mRNA) immunogene therapy.

Experts share what they are looking forward to most at this year's European Hematology Association (EHA) Congress.

Amit Singal, MD, medical director of the Liver Tumor Program at UT Southwestern Medical Center, discussed the current outlook for patients with hepatocellular carcinoma (HCC) and how to choose between therapies.

Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).

The 2024 European Hematology Association (EHA) Congress, convening virtually and in Madrid, Spain, from June 13-16, 2024, will feature practice-changing findings in hematology and oncology, as well as ample networking opportunities and conversations about the future of the field.

There may be a causal relaPatients with hyperthyroidism are at increased risk of ovarian cancer (OC), although the link between the conditions is not yet fully understood.

This study evaluated whether limited English proficiency modifies the association between cardiovascular risk factors or cardiovascular disease and outcomes in patients hospitalized with COVID-19.

Although further research is needed, these new findings suggest that using the 2 intranasal sprays is an effective option for patients with myasthenia gravis (MG) who experience eyelid drooping.

Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, explained the phase 3 BOREAS and NOTUS trials demonstrated comparable safety profiles for dupilumab in treating patients with chronic obstructive pulmonary disease (COPD).